

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Novartis Animal Health US, Inc.	02/19/2010
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	Novartis AG
<b>Street Address:</b>	Lichtstrasse 35
<b>City:</b>	4056 Basel
<b>State/Country:</b>	SWITZERLAND
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	10433811
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(336)387-1601
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
<b>Phone:</b>	336-387-1601
<b>Email:</b>	todd.sladek@novartis.com
<b>Correspondent Name:</b>	Todd Sladek
<b>Address Line 1:</b>	3200 Northline Ave., Ste. 300
<b>Address Line 2:</b>	Novartis Animal Health US, Inc.
<b>Address Line 4:</b>	Greenboro, NORTH CAROLINA 27408
<b>ATTORNEY DOCKET NUMBER:</b>	PAT031682-US-PCT
<b>NAME OF SUBMITTER:</b>	Todd Sladek
<b>Total Attachments: 1</b> source=31682#page1.tif	

**CH \$40.00 10433811**

**ASSIGNMENT**

For good and valuable consideration, the receipt and adequacy of which is hereby acknowledged,

**Novartis Animal Health US, Inc.**  
**3200 Northline Ave., Suite 300**  
**Greensboro, North Carolina 27408**  
**USA**

does hereby sell, assign and transfer to **Novartis AG** (Novartis AG hereinafter referred to as the "**ASSIGNEE**"), a company organized under the laws of the Swiss Confederation, of Lichtstrasse 35, 4056 Basel, Switzerland, and its successors, assigns and legal representatives, all our right, title and interest in and to the United States patent application set forth below, and any US patent issuing from this application, and the inventions claimed therein:

**United States Patent Application, Ser. No. 10/433,811**, filed June 6, 2003

to be held and enjoyed by said **ASSIGNEE**, their successors, assigns and legal representatives, to the full ends of the terms for which the patent is granted, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made.

Executed this 19<sup>th</sup> day of February, 2010.

  
Name: \_\_\_\_\_

Brian Reeve  
Vice President & General Counsel  
Novartis Animal Health US, Inc.